This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. CPD dashboard

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. CPD dashboard

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD hours. Upgrade to Pro

STREAM trial - discontinuing statins in older adults without cardiovascular disease

Authoring team

  • The STREAM trial was an international, open-label, randomised, controlled trial evaluating whether discontinuing statin therapy in older adults with multimorbidity but no known cardiovascular disease is non-inferior to continuing therapy.
  • Background: whether discontinuing statin therapy in older adults with at least two chronic conditions and no history of cardiovascular disease affects time to a first cardiovascular event or death had not been well characterised.

Study design and population

  • Population: 1880 community-dwelling adults aged 70 years or older (mean age 77.5 years, 46.9% women) taking statins for primary prevention with at least two chronic conditions.
  • Intervention: participants were randomly assigned in a 1:1 ratio to either discontinue (n=938) or continue (n=942) statin therapy and other lipid-lowering therapies.
  • Primary outcome: a composite of nonfatal myocardial infarction, non-fatal ischaemic stroke or death from any cause, whichever occurred first.
  • Non-inferiority criteria: assessed on the basis of the between-group difference in restricted mean event-free survival time at 2 years, using a predefined non-inferiority margin of −5.2 weeks.

Key findings and results

  • Primary outcome non-inferiority: the between-group difference in restricted mean event-free survival time at 2 years was −2.0 weeks (95% CI, −3.7 to −0.3; P<0.001 for non-inferiority), satisfying the predefined non-inferiority threshold.
  • Event rates: over a median follow-up of 103 weeks (approximately 2 years), primary outcome events occurred in 119 participants (12.7%) in the discontinuation group compared to 87 participants (9.2%) in the continuation group.
  • Safety and serious adverse events: at least one serious adverse event occurred in 43.0% of participants in the discontinuation group and in 39.8% of participants in the continuation group.

Primary care takeaway

  • Among older adults (aged 70 years and older) with multimorbidity (at least two chronic conditions) receiving statins for primary prevention, discontinuing statins was non-inferior to continuing treatment regarding 2-year major cardiovascular events or all-cause mortality.
  • Provides supportive clinical evidence for shared decision-making, polypharmacy management, and rational deprescribing of primary prevention statins in older patients.

Reference:

 


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.